In a combined analysis of two phase II investigations,median PFS and OS were 8.9 weeks and 20.4 weeks, respectively (Table 4).80 The DCRwas 24.1% and the regimen was well tolerated.80 The authors analysedoutcomes according to PD-L1 expression and observed no significant differencebetween response or survival in participants with PD-L1-positiveversus negative tumours.80 Notably, 31% ofparticipants had well-differentiated NENs and only 42% had a Ki-67 > 50%,once again limiting translational impact in the context of NEC. This evidence concerns the gene MKI67 and neuroendocrine carcinoma.